416 related articles for article (PubMed ID: 10914543)
1. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
4. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
[TBL] [Abstract][Full Text] [Related]
8. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
10. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Creutzig U; Harbott J; Sperling C; Ritter J; Zimmermann M; Löffler H; Riehm H; Schellong G; Ludwig WD
Blood; 1995 Oct; 86(8):3097-108. PubMed ID: 7579404
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821.
Raimondi SC; Chang MN; Ravindranath Y; Behm FG; Gresik MV; Steuber CP; Weinstein HJ; Carroll AJ
Blood; 1999 Dec; 94(11):3707-16. PubMed ID: 10572083
[TBL] [Abstract][Full Text] [Related]
14. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Razzouk BI; Raimondi SC; Srivastava DK; Pritchard M; Behm FG; Tong X; Sandlund JT; Rubnitz JE; Pui CH; Ribeiro RC
Leukemia; 2001 Sep; 15(9):1326-30. PubMed ID: 11516092
[TBL] [Abstract][Full Text] [Related]
15. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
16. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Delaunay J; Vey N; Leblanc T; Fenaux P; Rigal-Huguet F; Witz F; Lamy T; Auvrignon A; Blaise D; Pigneux A; Mugneret F; Bastard C; Dastugue N; Van den Akker J; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Dombret H; ; ; ; ;
Blood; 2003 Jul; 102(2):462-9. PubMed ID: 12649129
[TBL] [Abstract][Full Text] [Related]
18. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
20. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
